Evidence map›Paper›PMID 38675727›Full record

ArticleVaccines2024

Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVac

Nina Dwi Putri, Aqila Sakina Zhafira, Pratama Wicaksana, Robert Sinto, Gryselda Hanafi, Lowilius Wiyono, Ari Prayitno, Mulya Rahma Karyanti, Murni Luciana Naibaho, Febrina Febrina and 11 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Nina Dwi PutriFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
Aqila Sakina ZhafiraFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
Pratama WicaksanaFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
Robert SintoFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
Gryselda HanafiFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
Lowilius WiyonoFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.ORCID 0000-0001-5018-7676
Ari PrayitnoFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
Mulya Rahma KaryantiFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
Murni Luciana NaibahoCempaka Putih Public Health Center, Jakarta 10520, Indonesia.
Febrina FebrinaCempaka Putih Public Health Center, Jakarta 10520, Indonesia.
Hadyana SukandarFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
Vivi SetiawatyNational Institute of Health Research & Development, Jakarta 14530, Indonesia.ORCID 0000-0002-1196-7909
Mursinah MursinahNational Institute of Health Research & Development, Jakarta 14530, Indonesia.
Ahmat Rediansya PutraDiagnostic and Research Center, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
Heri WibowoDiagnostic and Research Center, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.
Julitasari SundoroThe Indonesian Technical Advisory Group on Immunization, Jakarta 10430, Indonesia.
Hindra Irawan SatariFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
Dwi OktaviaJakarta Health Agency, Jakarta 10160, Indonesia.
Pretty MultihartinaNational Institute of Health Research & Development, Jakarta 14530, Indonesia.
Dante Saksono HarbuwonoMinistry of Health of Republic of Indonesia, Jakarta 12750, Indonesia.
Sri Rezeki HadinegoroFaculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
University of Indonesia · IDMinistry of Health · IDIndonesian Pediatric Society · ID

Funding

Ministry of Health LB.02.01/2/KE.014/2022
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) has been extensively researched, particularly with regard to COVID-19 vaccines. However, issues with logistics and availability might cause delays in vaccination programs. Thus, the efficacy and safety of half-dose heterologous mRNA should be explored. This was an open-label observational study to evaluate the immunogenicity and safety of half-dose mRNA-1273 as a booster vaccine among adults aged >18 years who underwent a complete primary SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination regimen with CoronaVac

Indexed as

boosterCOVID-19efficacyhalf-dosemRNAsafetyvaccine

Identifiers

PMID38675727
PMCPMC11053985
OpenAlexW4393094378

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.